Tuesday,02 April 2024 09:11:24

Market Report by Email

If you would like to receive the daily Market Report by email please fill out your name and email address in the sign-up form below and you will be added to our mailing list.

Tuesday,02 April 2024 at 08:09

UK and European stocks opened higher as major markets returned to action after the Easter weekend and investors looked ahead to the start of a new trading quarter.

Hong Kong stocks led gains in Asia-Pacific markets as Xiaomi shares surged, while investors assessed economic data from South Korea and Australia.

Gold prices hovered below record highs hit in the previous session, as the U.S. dollar and Treasury yields held firm after strong U.S. data flagged doubts on whether the Federal Reserve would deliver three interest rate cuts this year.

Oil prices gained in early Asian trading, underpinned by signs of improved demand and escalating Middle East tensions that had sparked a rally in U.S. futures to a five-month high in the previous session.

In corporate news, America's drug regulator gave the green light to AstraZeneca for the add-on use of Voydeva in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH was the condition in which red blood cells outside of blood vessels were destroyed.

Voydeva could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

Markets

At 08:30

FTSE 100 7,999 +0.58%

FTSE 250 19,958 +0.37%

DAX 18,541 +0.26%

At the close

Dow Jones 39,566 (-0.60%)

S&P 500 5,243 (-0.20%)

NASDAQ 16,396 +0.11%

Fixed Income

UK 10-YR YIELD 4.025

Exchange Rates

GBP/USD 1.254

GBP/EUR 1.169

Commodities

Gold $2,253 +0.14%

Brent $88.30 +0.77%

Important - No news or research item should be construed as a recommendation to trade. The inclusion of securities within this report does not necessarily imply their suitability for individual portfolios or situations in respect of which further advice should be sought. Information contained in this report has been compiled from sources believed to be reliable but is not warranted to be accurate or complete.